Endocrinol Metab.  2015 Jun;30(2):231-232. 10.3803/EnM.2015.30.2.231.

Letter: Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance (Endocrinol Metab 2014;29:536-44, Min Jung Jung et al.)

• Park D
• Lee EK

• KMID: 2282016
• DOI: http://doi.org/10.3803/EnM.2015.30.2.231

Abstract

No abstract available.

MeSH Terms

Glucagon-Like Peptide 1*
Thyroid Neoplasms*
Glucagon-Like Peptide-1 Receptor
Glucagon-Like Peptide 1

Reference

1. American Diabetes Association. Standards of medical care in diabetes: 2014. Diabetes Care. 2014; 37:Suppl 1. S14–S80.

2. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368:1696–1705.

3. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology. 2000; 141:4600–4605.

4. Jung MJ, Kwon SK. Expression of glucagon-like Peptide-1 receptor in papillary thyroid carcinoma and its clinicopathologic significance. Endocrinol Metab (Seoul). 2014; 29:536–544.

5. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995; 48:876–878.